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PNSAIDs and Myocardial Infarction
Role of Dose Potency in the Prediction of Risk of
Myocardial Infarction Associated With Nonsteroidal
Anti-Inflammatory Drugs in the General Population
Luis Alberto Garcı´a Rodrı´guez, MD,* Stefania Tacconelli, PHD,† Paola Patrignani, PHD†
Madrid, Spain; and Chieti, Italy
Objectives We studied the association between the frequency, dose, and duration of different nonsteroidal anti-
inflammatory drugs (NSAIDs) and the risk of myocardial infarction (MI) in the general population. We verified
whether the degree of inhibition of whole blood cyclooxygenase (COX)-2 by average circulating drug levels can
be a surrogate biochemical predictor of the risk of MI by NSAIDs.
Background There is evidence that both traditional NSAIDs and selective inhibitors of COX-2 may increase the risk of MI.
Methods From the THIN (The Health Improvement Network) database, we identified 8,852 cases of nonfatal MI in pa-
tients 50 to 84 years old between 2000 and 2005 and conducted a nested case-control analysis. We correlated
the risk of MI with the degree of inhibition of platelet COX-1 and monocyte COX-2 in vitro by average therapeutic
concentrations of individual NSAIDs.
Results The risk of MI was increased with current use of NSAIDs (relative risk [RR]: 1.35; 95% confidence interval [CI]:
1.23 to 1.48). The risk increased with treatment duration and daily dose. We found a significant correlation be-
tween the degree of inhibition in vitro of whole blood COX-2 (r2  0.7458, p  0.0027), but not whole blood
COX-1 (r2  0.0007, p  0.947), and the risk of MI associated with individual NSAIDs that lacked complete sup-
pression (95%) of platelet COX-1 activity. Individual NSAIDs with a degree of COX-2 inhibition 90% at thera-
peutic concentrations presented an RR of 1.18 (95% CI: 1.02 to 1.38), whereas those with a greater COX-2 inhi-
bition had an RR of 1.60 (95% CI: 1.41 to 1.81).
Conclusions Our findings suggest that the variable risk of MI among NSAIDs that do not inhibit platelet COX-1 completely and
persistently is largely related to their extent of COX-2 inhibition. (J Am Coll Cardiol 2008;52:1628–36) © 2008
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.041i
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ronsteroidal anti-inflammatory drugs (NSAIDs), a chem-
cally heterogeneous group of agents that comprises tradi-
ional (t)NSAIDs and NSAIDs selective for cyclooxygenase
COX)-2 (coxibs), are commonly used in the general
opulation for treating pain and inflammatory conditions.
hey act mostly through the inhibition of COX-2–
ependent prostanoids (1).
NSAIDs are distinguished on the basis of their COX-
sozyme selectivity in vitro, described as the ratio of the
oncentrations required to inhibit the activity of the
rom the *Centro Español de Investigacio´n Farmacoepidemiolo´gica (CEIFE),
adrid, Spain; and the †Department of Medicine and Center of Excellence on
ging, G. d’Annunzio University, School of Medicine, CeSI, Chieti, Italy. The
atabase portion (THIN) was funded by an unrestricted research grant from Pfizer to
EIFE. The corresponding author has full authorship rights to the manuscript and
as not obligated to include any Pfizer comments in the submitted manuscript. The
iochemistry study was supported by a grant from the European Community’s Sixth
ramework Program (Eicosanox, LSMH-CT-2004-005033) to Dr. Patrignani.s
Manuscript received May 2, 2008; revised manuscript received July 22, 2008,
ccepted August 6, 2008.sozymes by 50% (IC50 for COX-1/IC50 for COX-2).
his is assessed using the human whole blood assays that
valuate the effects of drugs on platelet COX-1 and mono-
yte COX-2 (2,3). They are capacity indexes of COX-
See page 1637
sozyme activities to generate prostanoids from endogenous
ources of arachidonic acid, and their pharmacological
nhibition is not influenced by different pathological condi-
ions. Thus, the dose of aspirin for cardioprotection selected
y the assessment of thromboxane (TX) B2 levels in the
hole blood assay in healthy and young subjects (4) was
ppropriate also for elderly patients with cardiovascular
CV) disease (5).
The assessment of COX-1/COX-2 ratios in vitro de-
cribes an experimental COX-isozyme selectivity that mir-
ors the chemical features of the different NSAIDs. It
howed that COX-2 selectivity of NSAIDs is a continuous
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he whole blood assays also permit estimation of achieved
OX-isozyme selectivity in humans, which is the ratio of
sozyme inhibition at a given plasma concentration. Impor-
antly, achieved selectivity of NSAIDs varies as a consequence
f the dose administered.
The introduction of NSAIDs selective for COX-2, which
ere developed to reduce the risk of serious gastrointestinal
omplications— dependent, at least in part, on the inhibition
f COX-1—while achieving comparable efficacy, has raised
ew concerns now centered on CV safety (7). Originally, these
oncerns were reported solely for coxibs. Subsequently, we have
earned that some tNSAIDs may share a CV risk similar to
elective COX-2 inhibitors. The body of evidence consists of
ata from clinical trials (8) and from a growing number of
bservational studies, most of which have been performed
sing large automated databases (9).
Inhibition of TXA2-dependent platelet function in vivo
ccurs when platelet COX-1– dependent capacity to syn-
hesize TXA2 (as assessed by measuring serum TXB2 levels)
s reduced 95% (10). In fact, recent findings suggest that
ocal release of tiny concentrations of TXA2 from activated
latelets may play an important role in platelet thrombus
ormation. They activate the tyrosine-kinase– based signal-
ng pathway (11), which may translate into full platelet
ctivation in the presence of weak platelet agonists or
ubthreshold concentrations of stronger agonists. This leads
o the concept of functional COX-2 selectivity by NSAIDs,
amely, inhibition of COX-2 in the presence of an insuf-
cient reduction of platelet COX-1 activity to translate into
nhibition of platelet function.
In the present study, we used data from the THIN (The
ealth Improvement Network) database to evaluate the
ssociation between prospectively collected information on
he frequency, dose, and duration of different types of
SAIDs and the risk of nonfatal myocardial infarction
MI) in the general population. Additionally, we verified the
unctional COX-2 selectivity by average circulating concen-
rations of the doses of tNSAIDs and coxibs, mostly taken
rom the population of the THIN database, and found that
ost tNSAIDs were as COX-2 selective as coxibs with
espect to platelet function. Then, we aimed to address the
ypothesis that the degree of inhibition of whole blood
OX-2 in vitro by plasma concentrations corresponding to
he average NSAID therapeutic dose in patients (an index
f drug potency/exposure) (12–14) predicts the relative risk
RR) of MI for each individual NSAID functionally selec-
ive for COX-2 observed in the general population.
ethods
detailed description of the methods used in the THIN
nalysis can be found in the Online Appendix.
HIN nested case-control study. We conducted a
opulation-based, retrospective cohort study with nested
ase-control analysis using data from the THIN database in fihe United Kingdom (15). The
tudy cohort included patients
ges 50 to 84 years between Jan-
ary 2000 and October 2005
ith at least 2 years of enroll-
ent with the general practitio-
er and at least 1 health contact
n the previous 3 years before
heir start date. Patients with
ancer were excluded from the
ohort. All members of this co-
ort were followed up from the
tart date until the earliest occur-
ence of one of the following end
oints: MI detection, cancer,
5th birthday, death, or end of
tudy period. The final cohort
onsisted of 716,395 persons fol-
owed up for an average of 4.1
ears.
We applied similar methods of case ascertainment and
alidation as performed in 2 recent studies (16,17). We
dentified patients with a recorded diagnosis of MI during
he study period (n  12,499), resulting in 10,653 patients
onsidered incident cases of MI after review of their
omputerized patient profile. We then validated a random
ample of 500 patients with the primary care physicians.
he collaboration of the primary care physicians was excel-
ent (response rate of 91%), and we achieved a similar high
onfirmation rate (95%) compared with previous studies
16,17). We retained for the analysis nonfatal incident cases
f MI, defined as patients alive within 1 month after the
ccurrence of MI; the final number of cases was 8,852. A
roup of 20,000 control subjects were randomly selected
rom the list of eligible person-days (index date) and
requency matched to the cases on sex, age within 1 year,
nd calendar year.
We categorized exposure to NSAIDs into mutually
xclusive time windows: current, when the supply of the
ost recent prescription lasted until index date or ended in
he 7 days before the index date; recent, when it ended
etween 8 and 90 days before the index date; past, when it
nded between 91 and 365 days before the index date; and
onuse, when there was no recorded use in the year before
he index date. The category of current use was further
ubdivided: single, when there was use of only 1 individual
SAID within the month before the index date; multiple,
hen the patient received prescriptions for 2 or more individ-
al NSAIDs within the week before the index date; and
witcher, when there was use of only 1 NSAID in the week
efore the index date but there was use of at least 1 other
SAID in the window 8 to 30 days before the index date.
Among current single users, we evaluated the effect of
SAIDs according to duration, dose, and plasma half-life/
ormulation. We analyzed the risk among new users, de-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
COX  cyclooxygenase
coxibs  selective
inhibitors of COX-2
CV  cardiovascular
MI  myocardial infarction
NSAID  nonsteroidal anti-
inflammatory drug
RR  relative risk
tNSAID  traditional
nonsteroidal anti-
inflammatory drug
TX  thromboxanened as patients who were free of any NSAID use in the
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Traditional NSAIDs, Coxibs, and MI November 11, 2008:1628–36ear preceding the first NSAID prescription after start date
18). We also performed a sensitivity analysis using a 0 to 30
ays time window to define current use.
n vitro whole blood assays. We selected the specific
utoff values in milligrams between low-medium daily dose
nd high daily dose of NSAIDs used in the THIN popu-
ation. The inhibitory effects toward platelet COX-1 and
onocyte COX-2 by therapeutic concentrations of different
SAIDs (12–14) were determined in vitro using the human
hole blood assays (3,4). The doses (Cmax) were as
ollows: naproxen 750 mg (253 M), ibuprofen 1,200 mg
39 M), meloxicam 7.5 mg (3 M), celecoxib 200 mg
1.8 M), rofecoxib 25 mg (1 M), indomethacin 75
g (3 M), etoricoxib 90 mg (3.6 M), diclofenac 100 mg
0.8 M), piroxicam 20 mg (16.6 M), and etodolac SR
00 mg (26 M). Peripheral venous blood samples were
ithdrawn from 10 healthy subjects (ages 22 to 35 years),
ho gave their written informed consent. The in vitro study
as approved by the local ethics committee, and it did not
eed Institutional Review Board review.
tatistical analysis. We estimated the odds ratio and 95%
onfidence intervals (CIs) for MI associated with NSAID
se compared with nonuse using unconditional logistic
egression with Statview 5.0.1 (SAS Institute, Cary, North
arolina). The mechanism of control sampling used in our
tudy (known as incidence density sampling) means that the
ikelihood of being selected as a control is proportional to
he person-time at risk (19). Under this design, the odds
atio is an unbiased estimator of the incidence rate ratio, also
ommonly referred as RR. Conditional logistic regression
odels stratified for matching factors (age, sex, and calendar
ear) produced similar results (data not shown). We used a
value0.05 as the threshold of statistical significance. We
djusted for matching variables, use of other medications
aspirin, antihypertensive drugs, statins, other lipid-
owering drugs, oral steroids, and warfarin), comorbidity
diabetes mellitus, hypertension, hyperlipidemia, rheuma-
oid arthritis, osteoarthritis, anemia, coronary artery disease
CAD], and cerebrovascular disease), smoking, body mass
ndex, and health care utilization indicators. Variables that
hanged the estimates of NSAID use by 10% or more were
ncluded in the multivariable model. Specific stratified
nalyses were performed by sex, age, and history of CAD.
inear regression analysis was performed using InStat
GraphPad, San Diego, California) to estimate correlations
etween relative risk obtained from the THIN study and
ndexes of COX inhibition of individual NSAIDs.
oncentration-response curves were fitted and IC50 (drug
oncentration required for obtaining 50% of inhibition)
alues were analyzed with PRISM (GraphPad).
esults
he overall incidence rate of nonfatal MI in our population,
ges 50 to 85 years, was 4.1/1,000 person-years. The
ncidence was much greater among patients with anteced- tnts of CAD (13.9) than among those without a history of
AD (3.0). Table 1 shows the risk associated with use of
SAIDs. The estimate of RR of MI with current single
SAID use was 1.35 (95% CI: 1.23 to 1.48). NSAID users
ho stopped treatment between 3 months and 1 year in
dvance had a risk similar to that of nonusers (RR: 1.02,
5% CI: 0.94 to 1.12). The RR of MI was 1.13 (95% CI:
.92 to 1.39) among current users in their first month of
reatment and 1.53 (95% CI: 1.28 to 1.82) when taking
SAIDs for 3 years. There was also a greater risk among
sers of high dose compared with users of low-medium dose
RR: 1.28, 95% CI: 1.07 to 1.53).
Table 2 shows RRs of MI according to plasma half-life
nd formulation. Users of slow-release formulations had an
R of 1.22 (95% CI: 0.96 to 1.54) compared with users of
he regular formulation. When daily dose was taken into
ccount, the slightly greater risk among users of the slow-
elease formulation was only observed in the low-medium
ose category.
Figure 1A shows the estimates of RR for individual
SAIDs. Most of them presented an RR compatible with
small increased risk or no increased risk, although the
mount of information was insufficient to provide precise
stimates. Only diclofenac and rofecoxib use were clearly
ssociated with a greater risk of MI (RR: 1.67, 95% CI: 1.44
elative Risk of MI According to Use,re m nt Duration, and Daily Dose of NSAIDs*
Table 1 Relative Risk of MI According to Use,Treatment Duration, and Daily Dose of NSAIDs*
NSAID Exposure
Controls
(n  20,000)
MI Cases
(n  8,852) RR (95% CI)
Recency
Nonuse 15,513 6,434 Reference
Current use 1,570 940 1.34 (1.23–1.47)
Single 1,510 901 1.35 (1.23–1.48)
Multiple 33 20 1.27 (0.71–2.27)
Switcher 27 19 1.14 (0.61–2.13)
Recent use 1,061 598 1.27 (1.14–1.42)
Past use 1,856 880 1.02 (0.94–1.12)
Duration
30 days 318 152 1.13 (0.92–1.39)
31–365 days 506 295 1.34 (1.15–1.56)
1–3 years 339 214 1.39 (1.16–1.67)
3 years 347 240 1.53 (1.28–1.82)
Daily dose†
Low-medium dose 963 521 1.23 (1.09–1.38)
High dose 547 380 1.57 (1.36–1.81)
Relative risk (RR) adjusted for age, sex, calendar year, body mass index, general practitioner
isits, referrals, smoking, Townsend score, ischemic heart disease, diabetes mellitus, rheumatoid
rthritis, chronic obstructive pulmonary disease, and anticoagulants, antihypertensives, oral ste-
oids, and aspirin use. †Specific cutoff values for dose (in mg) were as follows: aceclofenac 200,
cemetacin 120, azapropazone 600, celecoxib 200, diclofenac 100, diflunisal 1,500, etodolac
00, etoricoxib 90, fenbufen 900, fenoprofen 1,200, flurbiprofen 150, ibuprofen 1,200, indometh-
cin 75, ketoprofen 150, ketorolac 30, mefenamic acid 1,000, meloxicam 7.5, nabumetone
,000, naproxen 750, piroxicam 10, rofecoxib 25, sulindac 200, tenoxicam 10, tiaprofenic 600,
nd valdecoxib 20. Doses less than or equal to the cutoff value were grouped under low-medium
oses, and doses greater than the cutoff value were grouped under high doses.
CI  confidence interval; MI  myocardial infarction; NSAID  nonsteroidal anti-inflammatory
rug.o 1.94; and RR: 1.46, 95% CI: 1.10 to 1.92, respectively).
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November 11, 2008:1628–36 Traditional NSAIDs, Coxibs, and MIIn Figure 1B, we reported the degree of inhibition on
hole blood COX-1 and -2 activities in vitro produced by
herapeutic concentrations of individual NSAIDs. Except
or naproxen and ibuprofen, all other NSAIDs inhibited
OX-2 more profoundly than COX-1 at therapeutic con-
entrations. Importantly, platelet COX-1 was suppressed at
he functional range, namely, 95% (10) by therapeutic
oses of naproxen but no other NSAIDs.
In Figure 1C, we reported a statistically significant
orrelation (r2 0.7458, p 0.0027) between the degree of
nhibition of whole blood COX-2 in vitro produced by
verage circulating therapeutic concentrations and the RR
f MI associated with individual NSAIDs: naproxen, which
as an effect on platelet COX-1 activity compatible with
nhibition of platelet function, was not included. When we
rouped individual NSAIDs with a degree of COX-2
nhibition 90% at therapeutic dose (ibuprofen, meloxi-
am, celecoxib, and etoricoxib), users of these NSAIDs
resented an RR of 1.18 (95% CI: 1.02 to 1.38), whereas
sers of rofecoxib, indomethacin, diclofenac, and piroxicam
COX-2 inhibition 90%) had an RR of 1.60 (95% CI:
.41 to 1.81, p for interaction 0.01).
The effect of dose for individual NSAIDs is shown in
able 3; among users of ibuprofen, the RR for doses up to
,200 mg daily was 1.00 (95% CI: 0.80 to 1.25), and it was
.56 (95% CI: 0.90 to 2.71) for doses above 1,200 mg
mainly 1,800 mg). Accordingly, average drug concentra-
ions after dosing with low and high doses of ibuprofen (39
nd 111 M, respectively) (8) inhibited whole blood
OX-2 activity by 75% and 90%, respectively. Figure 2
hows in more detail the effect of dose among users of
iclofenac. A clear dose-response was observed (p for trend
Relative Risk of MI According to Plasma Half-Liand Release F rmulation of NSAIDs and Stratifie
Table 2 Relative Risk of MI According to Pland Release Formulation of NSAIDs
Cases (n  8,852)
Overall
Nonuse 6,434
Short/no slow release† 498
Long/no slow release‡ 250
Slow release§ 153
Low-medium dose
Nonuse 6,434
Short/no slow release† 300
Long/no slow release‡ 154
Slow release§ 67
High dose
Nonuse 6,434
Short/no slow release† 198
Long/no slow release‡ 96
Slow release§ 86
*RR adjusted for age, sex, calendar year, body mass index, general pr
diabetes mellitus, rheumatoid arthritis, chronic obstructive pulmonary
†Short half-life group: aceclofenac, acemetacin, celecoxib, diclofen
ketoprofen, mefenamic acid, tiaprofenic acid, and valdecoxib. ‡Lon
sulindac, tenoxicam, rofecoxib and etoricoxib. §Slow-release group: ib
Abbreviations as in Table 1.0.0001): users of diclofenac 50 mg daily carried an RR of w.12 (95% CI: 0.57 to 2.19), and the corresponding estimate
mong users of 150 mg was 1.80 (95% CI: 1.49 to 2.18).
lso, the risk was slightly greater when diclofenac was
dministered as slow release compared with the plain form,
ven after adjusting for the dose.
We looked at whether the effect of aspirin on MI was
ffected by concomitant use of NSAIDs (Table 4). None of
he terms for interaction was statistically significant, al-
hough only concomitant use with ibuprofen and naproxen
uggested a minor antagonism: the corresponding estimates
f relative excess risk due to interaction were 0.16 and 0.22.
When we restricted the analysis to new users of NSAIDs,
he overall estimates of risk were similar according to
uration and daily dose. Also, there were only minor
ariations in risk among individual NSAIDs; the corre-
ponding RR among new users of rofecoxib was 1.57 (95%
I: 1.17 to 2.11). No differences were observed in the
stimates of RR with a more liberal definition of current use
supply of NSAID lasting until index date or ending in the
onth before index date) according to recency, duration, or
aily dose of NSAIDs (data not shown). We also performed
tratified analyses by sex, age, and history of CAD. The
verall effect of NSAID use did not seem to be modified by
ex, although the RR was slightly higher among females but
ot statistically significant (data not shown). The relative
isk decreased with advancing age. Users of NSAIDs who
ere 50 to 59 years old presented an RR of 1.61 (95% CI:
.27 to 2.04); the corresponding estimates among patients
ges 60 to 74 and 75 to 84 years old were 1.34 (95% CI: 1.18
o 1.53) and 1.22 (95% CI: 1.03 to 1.45), respectively. The
Rs of MI associated with NSAID use in patients with and
Daily Dose*
Half-Life
Stratified by Daily Dose*
ntrols (n  20,000) RR 95% CI
15,513 Reference
867 1.33 1.18–1.50
425 1.27 1.07–1.50
218 1.59 1.28–1.98
15,513 Reference
599 1.16 1.00–1.35
270 1.22 0.99–1.51
94 1.65 1.19–2.29
15,513 Reference
268 1.71 1.41–2.08
155 1.35 1.03–1.76
124 1.55 1.16–2.07
er visits, referrals, smoking, Townsend score, ischemic heart disease,
, and anticoagulants, antihypertensives, oral steroids, and aspirin use.
dolac, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indomethacin,
ife group: apazone, meloxicam, nabumetone, naproxen, piroxicam,
, indomethacin, etodolac, diclofenac, and ketoprofen.fed by
asma
and
Co
actition
disease
ac, eto
g half-lithout antecedents of CADwere 1.18 (95% CI: 0.98 to 1.42)
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tratum-specific CIs within each covariate were overlapping.
iscussion
n this nested case-control study with 8,852 incident nonfatal
I cases, we found that patients taking NSAIDs had a 35%
ncreased risk of MI. The excess risk of MI was observed after
month of treatment and appeared to slightly increase with
Figure 1 Degree of Inhibition of COX-2 by Average Circulating C
of Individual NSAIDs Functionally Selective for COX-2
(A) Relative risk (RR) and 95% confidence interval (CI) of MI according to use of in
centrations of NSAIDs on whole blood COX-1 (blue bars), mostly from platelets, an
functional range of inhibition of platelet COX-1, namely, 95% (9). (C) Relationshi
NSAIDs. Naproxen, which affects platelet COX-1 activity at functional range, is not
variables. It was performed using InStat (GraphPad, San Diego, California). Cele 
Indo  indomethacin; Melo  meloxicam; Piro  piroxicam; Rofe  rofecoxib.onger treatment duration. In addition to variable pharmaco- synamic features, members of the NSAID class share different
harmacokinetics, such as half-life, which was another inde-
endent predictor of the CV hazard. Also, increasing daily
ose, which determines the extent of COX-1 and -2 inhibition
n vivo, was a clear predictor of the corresponding risk of MI.
e were able to study the effect of dose and formulation in
ore detail with diclofenac: a gradual increase in risk accom-
anied each increasing dose of diclofenac as used in the general
opulation. Over and above the effect of dose, data for
ntrations
levant to RR of Nonfatal MI
al nonsteroidal anti-inflammatory drugs (NSAIDs). (B) Effects of therapeutic con-
-2 (green bars), mostly from monocytes, in vitro. The dotted line represents the
een degree of inhibition of whole blood COX-2 and RR of MI by individual
. The linear regression analysis yielded a significant correlation between the 2
oxib; Diclo  diclofenac; Etod  etodolac; Etori  etoricoxib; Ibu  ibuprofen;once
Is Re
dividu
d COX
p betw
shown
celeclow-release formulations of diclofenac suggested a greater risk
o
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November 11, 2008:1628–36 Traditional NSAIDs, Coxibs, and MIf MI, probably as a direct consequence of prolonged drug
xposure. This level of risk was greater than it was for any of
he ones shared by coxibs and reinforces the approach of
nalyzing the CV risk of each member of the large NSAID
Relative Risk of MI According to Daily Dose of I
Table 3 Relative Risk of MI According to Da
Individual NSAIDs Cases (n  8,852)
Nonuse 6,434
Celecoxib
Low-medium dose 76
High dose 5
Diclofenac
Low-medium dose 141
High dose 212
Ibuprofen
Low-medium dose 120
High dose 23
Indomethacin
Low-medium dose 16
High dose 13
Meloxicam
Low-medium dose 30
High dose 29
Naproxen
Low-medium dose 17
High dose 37
Rofecoxib
Low-medium dose 94
High dose 4
*RR adjusted for age, sex, calendar year, body mass index, general pr
diabetes mellitus, rheumatoid arthritis, chronic obstructive pulmonary
Specific cutoff values for dose (in mg) were as follows: celecoxib 200, d
750, and rofecoxib 25. Doses less than or equal to the cutoff value wer
were grouped under high doses.
Abbreviations as in Table 1.
Figure 2 Effect of Daily Dose and Formulation of Diclofenac on
Effect of the daily dose and formulation (slow release compared with plain) of dicl
is shown. The RR and 95% confidence interval of MI according to daily dose of dicamily individually (20). The incidence of MI was much
reater among patients with antecedents of CAD than it was
mong patients without a history of CAD. This finding is in
greement with the results of the recent celecoxib meta-
dual NSAIDs*
ose of Individual NSAIDs*
trols (n  20,000) RR 95% CI
15,513 1
134 1.35 1.00–1.82
10 1.05 0.33–3.35
216 1.51 1.20–1.89
267 1.80 1.49–2.18
279 1.00 0.80–1.25
35 1.56 0.90–2.71
22 1.58 0.80–3.10
23 1.36 0.67–2.79
46 1.40 0.87–2.27
53 1.21 0.75–1.94
46 0.90 0.50–1.60
73 1.12 0.74–1.69
138 1.41 1.07–1.87
1 6.50 0.70–60.33
er visits, referrals, smoking, Townsend score, ischemic heart disease,
, and anticoagulants, antihypertensives, oral steroids, and aspirin use.
ac 100, ibuprofen 1,200, indomethacin 75, meloxicam 7.5, naproxen
ed under low-medium doses, and doses greater than the cutoff value
f Nonfatal MI
on relative risk (RR) of nonfatal myocardial infarction (MI)
c are compared with nonuse and stratified by presentation form.ndivi
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t al. (22).
We found little evidence for a major effect modification
f the antiplatelet effect of aspirin among users of NSAIDs
23). Data were suggestive of a potential reduction of the
eneficial effect of aspirin only when taken together with
buprofen and naproxen, although there was substantial
tatistical imprecision when examining the presence of this
nteraction with individual NSAIDs. Yet, this is consistent
ith the results of clinical pharmacology showing that
buprofen and naproxen can interfere with the irreversible
nhibition of platelet COX-1 by aspirin (24–26).
We showed that pharmacodynamic and pharmacokinetic
eatures of individual NSAIDs are all important determi-
ants of CV hazard by COX inhibitors in the general
opulation. Among the NSAIDs studied, only naproxen
nd ibuprofen were more potent toward whole blood
OX-1 than COX-2 in vitro (6,27) (Fig. 2, Online Figs.
A and 1B). Thus, average therapeutic plasma concentra-
ions of these 2 NSAIDs may be associated with a balanced
nhibition of COX-1 and -2 (Fig. 1B). In contrast to
ow-dose ibuprofen, naproxen and high-dose ibuprofen may
uppress platelet COX-1 at the functional range, namely,
95% (10). Complete and perpetual suppression of platelet
OX-1 activity is mandatory to fulfill cardioprotection
ecause of a nonlinear relationship between inhibition of
latelet TXA2 generation and inhibition of TXA2-mediated
latelet aggregation: thus, an excess of 95% inhibition of
OX-1 activity is required to influence platelet function. In
act, even tiny concentrations of TXA2 can activate platelets
11). Naproxen and ibuprofen are characterized by different
harmacokinetics; in other words, naproxen has a long
alf-life (12 h), whereas ibuprofen has a short-half life
2 h) (12). Thus, complete and persistent suppression of
latelet COX-1 activity may occur in some users of
aproxen (27,28), but will be absent among users of low-
ose ibuprofen (the most prevalent use in the general
opulation) and rare among users of high-dose ibuprofen.
his impact on platelet COX-1 by naproxen might miti-
Relative Risk of Myocardial InfarctionAccording to Concomitant Use of Aspirin and NS
Table 4 Relative Risk of Myocardial InfarctiAccording to Concomitant Use of A
Aspirin Alone
RR (95% CI)
NSAID Alo
RR (95%
All NSAIDs 1.04 (0.96–1.12) 1.39 (1.25–
Celecoxib 1.04 (0.96–1.12) 1.44 (1.04–
Diclofenac 1.03 (0.95–1.12) 1.79 (1.52–
Ibuprofen 1.04 (0.96–1.12) 1.02 (0.80–
Meloxicam 1.03 (0.95–1.12) 1.61 (1.09–
Naproxen 1.04 (0.96–1.12) 1.00 (0.68–
Rofecoxib 1.04 (0.96–1.12) 1.47 (1.06–
*RR adjusted for age, sex, calendar year, body mass index, general pr
diabetes mellitus, rheumatoid arthritis, chronic obstructive pulmonar
Reference group for estimates of RR is the same for all comparisons: n
indicated in the left column.
Abbreviations as in Table 1.ate, even if not obliterate, the hazard conferred by the orofound inhibition of COX-2–dependent prostacyclin
29,30). In fact, naproxen was associated with no increased
V risk. All other studied tNSAID and coxib results were
ore potent toward COX-2 in vitro, from 3- to 255-fold
rofecoxib) (Online Fig. 2). However, none presented a
attern of COX-1 inhibition compatible with prevention of
V events (10). These results showed that most tNSAIDs
re as COX-2 selective as coxibs with respect to platelet
unction, at therapeutic concentrations. For functional
OX-2 selective inhibitors, the degree of inhibition of
hole blood COX-2 by plasma concentrations correspond-
ng to the average NSAID therapeutic dose in patients
12–14), which is an index of drug potency/exposure,
redicted the RR of MI. When we replaced our estimates of
isk for individual NSAIDs with those reported in a recent
eta-analysis of observational studies (31), the correlation
as still acceptable (r2  0.7445, p  0.1372), although
ith less power as data were reported for only 4 NSAIDs.
Analyses of previous clinical studies with rofecoxib 25
g/day, celecoxib 200 mg twice a day, etoricoxib 90
g/day, naproxen 220 mg twice a day, and low-dose aspirin
00 mg/day allowed us to detect a statistically significant
elationship between the degree of inhibition of whole
lood COX-2 ex vivo and inhibition of prostacyclin in vivo
as assessed by the urinary levels of 2,3-dinor-6-keto-
GF1) (27,28) (P. Patrignani and S. Tacconelli, unpub-
ished data obtained with celecoxib, rofecoxib, and etori-
oxib, June 2006) (Online Fig. 3). This relationship
upports the notion that the CV hazard associated with the
dministration of coxibs and some tNSAIDs occurs through
common mechanism involving the inhibition of COX-2–
ependent prostacyclin (29,30). Failure to detect any corre-
ation (r2  0.0007, p  0.947) between the degree of
nhibition of whole blood COX-1 in vitro and the risk of
I by the same NSAIDs (Online Fig. 4) lends little support
o one hypothesis suggesting that stronger inhibition of
ndothelial COX-1 than platelet COX-1 could be the
echanism for the increased risk of thrombotic events by
NSAIDs and coxibs (32). In the same manner, after leaving
*
and NSAIDs*
Aspirin  NSAID†
RR (95% CI) p Value Interaction
1.33 (1.11–1.60) 0.36
1.13 (0.63–2.03) 0.86
1.41 (1.03–1.93) 0.61
1.22 (0.83–1.78) 0.14
0.78 (0.41–1.51) 0.17
1.26 (0.60–2.62) 0.33
1.51 (0.92–2.47) 0.49
er visits, referrals, smoking, Townsend score, ischemic heart disease,
se, and use of anticoagulants, antihypertensives, and oral steroids.
s of aspirin and NSAIDs. †NSAID refers to the specific NSAID exposureAIDs
on
spirin
ne†
CI)
1.55)
2.01)
2.12)
1.32)
2.40)
1.47)
2.05)
actition
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onuserut naproxen, which presents some functional suppression of
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November 11, 2008:1628–36 Traditional NSAIDs, Coxibs, and MIlatelet COX-1, the correlation observed between the achieved
OX-2 selectivity (ratio of degree of inhibition of COX-2
nd -1 at average plasma concentrations) and the risk of MI
as very poor (r2  0.028, p  0.665) (Online Fig. 5).
Another aspect to be considered is the consequence of the
nhibition of renal prostanoids by NSAIDs. In susceptible
atients, inhibition of prostanoid generation by tNSAIDs and
oxibs causes sodium retention with resulting edema and
ypertension (29). Similar to thrombogenesis, COX-1 inhibi-
ion may mitigate the consequence of COX-2 inhibition in the
idney. This is compatible with a COX-2–dependent source
f vasodilatory prostacyclin and COX-1–dependent origin of
asoconstrictors, like TXA2, in the kidney (29,33).
A few considerations need to be evaluated with respect to
he validity of our findings. A potential limitation of studies
sing computerized prescription data is underascertaining
ver-the-counter drug use. In our study, misclassification of
SAID exposure is expected to be small, as only ibuprofen
ould be purchased over the counter in the United Kingdom
uring the study period. This misclassification would tend
o be nondifferential, which, given the small magnitude of
he observed association, would have little or no effect on
ur results. Also, we did not have information on over-the-
ounter use of aspirin (mainly, short-term analgesic use).
et the degree of underestimation of aspirin use would be
imited in the current study, as prescriptions are free for
atients 60 years of age in the United Kingdom. That
eans the majority of patients requiring cardioprotective
spirin would be likely to receive it on prescription rather
han have to pay for the drug over the counter, as reflected
y the high prevalence of current low-dose aspirin use in our
ontrol series (18%). Myocardial infarction cases were
scertained through review of computerized files with
ree text comments available in a subset. We tested the
alidity of our case ascertainment in a random sample of
lose to 500 questionnaires sent to the general practitio-
ers, resulting in a high confirmation rate of 95%.
ctually, the overall incidence of MI in our source
opulation ages 50 to 85 years was slightly over 4 of 1,000
erson-years, in line with rates reported in previous
tudies (17).
onclusions
e propose that the extent of inhibition of COX-2–
ependent prostacyclin may represent an independent key
eterminant of the increased risk of MI among NSAIDs
ith nonfunctional suppression of platelet COX-1, a prop-
rty shared by most tNSAIDs and coxibs, and that the
ssessment of whole blood COX-2 may represent a surro-
ate end point to predict the CV risk of these drugs. It
ollows that the separation of NSAIDs into selective
OX-2 and nonselective COX-2 inhibitors adds little in
redicting the CV risk of NSAIDs, after taking into
ccount the dose potency (exposure) of the specific NSAID.cknowledgments
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